Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR1 | P32241 | 10/20 | 0.76 |
| ▸ | VIPR2 | P41587 | 13/20 | 0.73 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.66 |
| ▸ | GLP1R | P43220 | 4/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4329513 | 0.90 | VIPR1 (0.78) | VIPR1VIPR2GLP1RECE1MUS81 | |
| Aviptadil SCHEMBL29357337 | 0.90 | VIPR1 (0.84) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL31633486 | 0.88 | VIPR1 (0.68) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL29389724 | 0.87 | VIPR1 (0.79) | VIPR1VIPR2NR3C1GLP1RECE1 | |
| SCHEMBL29569801 | 0.87 | VIPR1 (0.79) | VIPR1VIPR2NR3C1GLP1RECE1 | |
| SCHEMBL29531990 | 0.87 | PTH1R (0.77) | VIPR1VIPR2GLP1RECE1MUS81 | |
| SCHEMBL31633484 | 0.87 | TFPI (0.67) | VIPR1VIPR2GLP1R | |
| SCHEMBL29664425 | 0.87 | GLP1R (0.72) | NR3C1GLP1RECE1MUS81 | |
| SCHEMBL31633480 | 0.87 | VIPR1 (0.66) | VIPR1VIPR2NR3C1GLP1RECE1 | |
| SCHEMBL31255179 | 0.86 | VIPR2 (0.69) | VIPR1VIPR2GLP1RECE1MUS81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |